Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing

Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis. Strong Biomarker Inhibition And Extended…